$22.17+0.12 (+0.54%)
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, Continental Europe, and Australia.
Trupanion, Inc. in the Financial Services sector is trading at $22.17. Wall Street consensus targets $39.75 (4 analysts), implying a +79.3% move over the next 12 months. The stock is currently near its 52-week low of $21.16, remaining 33.9% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other...
Trupanion’s latest analyst update comes with no change to the stock’s price target, which keeps the formal outlook exactly where it was before. Even without a fresh target or commentary to unpack, the absence of revisions can still indicate how analysts currently see the risk and reward trade off. As you read on, you will see how to track these kinds of updates so you can follow the evolving narrative around Trupanion more confidently over time. Stay updated as the Fair Value for Trupanion...
Insurance companies serve as the backbone of risk management, providing essential protection and financial security for individuals and businesses. But concerns about claims severity and tightening regulations have tempered enthusiasm, and over the past six months, the industry has pulled back by 4.9%. This performance is a stark contrast from the S&P 500’s 11% gain.
Investors need to pay close attention to TRUP stock based on the movements in the options market lately.
Accident and health insurers are gaining from underwriting growth, technology adoption and rising demand for supplemental coverage.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.